Articles related to BRAIN CANCER

Stay informed with the FDA’s latest update on temozolomide labeling, which includes new indications and safety guidelines crucial for treating specific brain tumors.

Exploring the power of focused ultrasound in disrupting the blood-brain barrier, Dr. Ahluwalia’s LIBERATE trial is set to revolutionize the treatment landscape for glioblastoma.

In this phase 3 nonrandomized controlled trial of 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) had a median OS of 19.3 months from randomization (22.4 months from surgery), while contemporaneous, matched external control patients receiving SOC had a median OS of 16.5 months from randomization; for patients with recurrent glioblastoma (rGBM), the median OS was 13.2 months from relapse in the DCVax-L group vs. 7.8 months in the external control cohort. Both in nGBM and rGBM, significant increases in the long-term tails of the survival curves were seen.

The FDA Oncologic Drugs Advisory Committee (ODAC) unanimously decided on October 28 that there is insufficient evidence to support the claim that the pediatric oncology drug 131-I-omburtamab improves overall survival. A radiolabeled antibody, 131-I-omburtamab was created to treat central nervous system/leptomeningeal (CNS/LM) metastases in pediatric patients with neuroblastoma.

A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial When compared to WBRT, SRS alone resulted in less cognitive deterioration among long-term survivors. The link between late cognitive deterioration and WBRT was clinically significant. A significant decrease in cognition (2 SD) was linked to a decrease in overall QOL. WBRT, on the other hand, improved intracranial tumor control. This study provides detailed information about cognitive function in this patient population over time.

Researchers have identified a small molecule, named as SHP656, that can target the brain’s clock proteins and may prove effective for treating glioblastoma.